Abiopharma

🔍 SPRINGER TIMOTHY A (Director)

Company: Cartesian Therapeutics, Inc. (RNAC)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 2,600 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,646,285.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: By wife | shares_owned_after: 330,695.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 656,513.00 | Footnotes: F2
• Acquired 7,800 shares of Stock Option (Right to Buy) at $6.76 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | Exercise: 2027-01-02 | equity_swap_involved: 0 | shares_owned_after: 7,800.00 | transaction_form_type: 4

Footnotes:

• F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
• F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.